Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8798315 | 0.86 | CA2 (0.35) | CA2CA1CA9CA7CA14 | |
| SCHEMBL13056220 | 0.84 | CA2 (0.38) | CA2CA1CA9TP53 | |
| SCHEMBL27951227 | 0.83 | CA2 (0.39) | CA2CA1CA9CA7CA14 | |
| SCHEMBL30608968 | 0.79 | CA2 (0.42) | CA2CA1CA9CA7TP53 | |
| SCHEMBL9274278 | 0.79 | GCLC (0.35) | — | |
| SCHEMBL12186661 | 0.79 | CA1 (0.30) | CA2CA1CA7CA14ENPEP | |
| SCHEMBL15354731 | 0.77 | NLRP3 (0.33) | — | |
| SCHEMBL5637131 | 0.77 | NLRP3 (0.33) | — | |
| SCHEMBL6729253 | 0.77 | — | — | |
| SCHEMBL224712 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | Sumitomo Pharma Co., Ltd. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4071239-A1 | METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS | Sumitomo Pharma Co., Ltd. (JP) | 2022-10-12 | — | — | EP | disclosed |
| CN-114901810-A | Method for culturing hematopoietic stem cells | 住友制药株式会社 | 2022-08-12 | — | — | CN | disclosed |
| EP-3325494-B1 | SELECTIVE INHIBITORS OF ALPHA2-CONTAINING ISOFORMS OF NA,K-ATPASE AND USE THEREOF FOR REDUCING INTRAOCULAR PRESSURE | YEDA RES & DEV (IL) | 2020-12-30 | — | — | EP | disclosed |
| EP-3191471-B1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2020-03-11 | — | — | EP | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| EP-3191471-A1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9550754-B2 | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-24 | — | — | US | disclosed |
| EP-2439204-B1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | NISSAN CHEMICAL IND LTD (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| EP-1112256-A1 | CYCLOHEXENONQUINOLINOYL-DERIVATIVES AS HERBICIDAL AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-04 | — | — | EP | disclosed |
| EP-1080089-A1 | PYRAZOLYLDIOXOTHIOCHROMANOYL DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000014069-A1 | CYCLOHEXENONQUINOLINOYL-DERIVATIVES AS HERBICIDAL AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-16 | — | — | WO | disclosed |
| WO-1999059991-A1 | PYRAZOLYLDIOXOTHIOCHROMANOYL DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-25 | — | — | WO | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| EP-0697407-B1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0697407-A1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | HCLS1, KIT, MCL1 | CA2 1709/4885CA1 864/4885CA9 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.